ArticleMedical science monitor : international medical journal of experimental and clinical research2025
Exploring the Association Between Serum Neurogranin, Nardilysin, and Ischemic Stroke: A Case-Control Study Conducted in the Emergency Department.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of stroke blood biomarker data highlights need for more translational research methods.Nature communications · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Ischemic stroke (IS) is a major cause of mortality and disability worldwide. Rapid and accurate diagnosis in the emergency department (ED) is crucial for improving outcomes. Neurogranin (Ng), a postsynaptic protein involved in synaptic plasticity, and Nardilysin (NRDC), a metallopeptidase with neuronal functions, have been linked to various neurological disorders. This study examines their potential diagnostic and prognostic value in IS. MATERIAL AND METHODS This prospective case-control study was carried out in a high-volume ED between June and October 2023. A total of 44 IS patients and 44 healthy controls, matched for age and sex, were included. Serum levels of Ng and NRDC were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analyses involved receiver operating characteristic (ROC) analysis to assess diagnostic value and comparisons of biochemical parameters between groups. RESULTS Ng levels were significantly higher in IS patients compared to controls (281.12±32.12 pg/mL vs 265.71±24.54 pg/mL, P=0.01), with moderate diagnostic accuracy (area under curve=0.624). Elevated Ng levels were associated with intensive care unit admission (311.50±46.13 pg/mL, P=0.023). NRDC levels showed no significant differences between groups or clinical outcomes. Biochemical parameters, including elevated urea and creatinine and reduced hemoglobin levels, showed the systemic impacts of IS. CONCLUSIONS Ng may have a limited role as a biomarker in IS diagnosis, while its potential prognostic value requires further validation. NRDC did not show significant utility in this study. Larger studies incorporating additional biomarkers are needed to determine whether Ng can provide clinical insights into IS diagnosis and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.